摘要
静脉注射免疫球蛋白(IVIG)是临床上推荐治疗暴发性心肌炎(FM)的一种药物治疗方案,其可通过抗病毒、抗炎、免疫调节等相关机制减少心肌细胞损伤,可能改善左室功能、降低恶性心律失常发生率,降低FM患者死亡率,在FM的治疗中具有一定的应用价值。但IVIG治疗FM的最佳时机、剂量和用法,以及对FM患者预后的影响仍有待进一步开展更多的前瞻性临床研究来明确。
Intravenous immunoglobulin(IVIG)therapy has been commonly used in the treatment of fulminant myocarditis(FM)in clinical practice,which may reduce myocardial cell injury,improve left ventricular function,and reduce the incidence of malignant arrhythmia and FM mortality by the antiviral,anti-inflammatory,and immunomodulatory effects.Therefore,IVIG has certain application value in the treatment of FM.However,the optimal timing,dosage and usage of IVIG in the treatment of FM,as well as its impact on the prognosis of FM patients still need to be elucidated by performing more high-quality prospective clinical trials in the future.
作者
苏冠华
夏彤
SU Guan-hua;XIA Tong(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430022,China)
出处
《内科急危重症杂志》
2022年第6期448-452,共5页
Journal of Critical Care In Internal Medicine
基金
国家自然科学基金资助项目(No:81700345)。